Fairvalue-Calculator Fairvalue-Calculator
EN DE

Venus Medtech (Hangzhou) Inc (VMTHF) Fair Value & Analysis

Healthcare · US · Market cap $186M

Price$0.4219
Fair Value$1.26
Upside+198.6%
Quality95/100
Evidence: Low Range $0.8300 – $1.58

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Venus Medtech (Hangzhou) Inc (VMTHF) currently trades at $0.4219, while our model-based Fair Value estimate is $1.26 — implying the stock looks roughly 198.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising ca…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is Venus Medtech (Hangzhou) Inc (VMTHF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.26 versus a price of $0.4219 — about +199% (undervalued). Model-based estimate, not financial advice.
What is the fair value of VMTHF?
Our 21-model fair value for Venus Medtech (Hangzhou) Inc is $1.26 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.4219.
What is the quality score of VMTHF?
Venus Medtech (Hangzhou) Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.